p-eEF2K Antibody (F-8): sc-377537

p-eEF2K Antibody (F-8) is a mouse monoclonal IgG1 antibody that detects eukaryotic elongation-factor-2 kinase (eEF2K) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). p-eEF2K (F-8) antibody plays a crucial role in understanding the regulation of protein synthesis, as eEF2K is a key kinase that modulates the elongation phase of translation by phosphorylating and inactivating eEF2. This process is vital for cellular responses to various stimuli, including stress and growth factors, as p-eEF2K directly influences the rate of polypeptide chain elongation. The phosphorylation of eEF2K at specific serine residues, such as Ser 359 and Ser 366, is essential for activity and regulation, with Ser 359 being particularly significant as insulin-like growth factor-1 and other growth factors influence this site. eEF2K integrates signals from multiple pathways, including those mediated by SAPK4 and p70 S6 kinase, highlighting p-eEF2K′s importance in cellular homeostasis and adaptation. Using anti-eEF2K antibody (F-8) enables researchers to gain insights into the intricate mechanisms of translation regulation and the physiological implications of eEF2K activity in various biological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-eEF2K Antibody (F-8) References:

1. Coupled activation and degradation of eEF2K regulates protein synthesis in response to genotoxic stress.  |  Kruiswijk, F., et al. 2012. Sci Signal. 5: ra40. PMID: 22669845
2. Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells.  |  Cheng, Y., et al. 2013. Autophagy. 9: 208-19. PMID: 23182879
3. Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.  |  Fu, LL., et al. 2014. Apoptosis. 19: 1527-31. PMID: 25023961
4. Repression of eEF2K transcription by NF-κB tunes translation elongation to inflammation and dsDNA-sensing.  |  Bianco, C., et al. 2019. Proc Natl Acad Sci U S A. 116: 22583-22590. PMID: 31636182
5. Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.  |  Zhang, B., et al. 2021. Int J Mol Sci. 22: PMID: 33673713
6. Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions.  |  Yoshimori, A., et al. 2021. Medicines (Basel). 8: PMID: 34065377
7. Functionally distinct roles for eEF2K in the control of ribosome availability and p-body abundance.  |  Smith, PR., et al. 2021. Nat Commun. 12: 6789. PMID: 34815424
8. Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation.  |  Fu, Q., et al. 2022. Molecules. 27: PMID: 35956836
9. Impact of silencing eEF2K expression on the malignant properties of chordoma.  |  Aydemir, E., et al. 2023. Mol Biol Rep. 50: 3011-3022. PMID: 36652154
10. eEF2K alleviates doxorubicin-induced cardiotoxicity by inhibiting GSK3β and improving autophagy dysfunction.  |  Guan, J., et al. 2024. Cell Biol Toxicol. 41: 15. PMID: 39708064

The preferred eEF2K antibody is eEF2K Antibody (C-12): sc-390710.